Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.

Piper ML, Wong J, Fahrner-Scott K, Ewing C, Alvarado M, Esserman LJ, Mukhtar RA.

NPJ Breast Cancer. 2019 Sep 6;5:29. doi: 10.1038/s41523-019-0125-7. eCollection 2019.

2.

Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.

Yu NY, Iftimi A, Yau C, Tobin NP, van 't Veer L, Hoadley KA, Benz CC, Nordenskjöld B, Fornander T, Stål O, Czene K, Esserman LJ, Lindström LS.

JAMA Oncol. 2019 Aug 8. doi: 10.1001/jamaoncol.2019.1856. [Epub ahead of print]

PMID:
31393518
3.

The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches.

Eklund M, Broglio K, Yau C, Connor JT, Stover Fiscalini A, Esserman LJ.

JNCI Cancer Spectr. 2019 Jan 8;2(4):pky067. doi: 10.1093/jncics/pky067. eCollection 2018 Oct.

4.

Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.

Dreher N, Hadeler EK, Hartman SJ, Wong EC, Acerbi I, Rugo HS, Majure MC, Chien AJ, Esserman LJ, Melisko ME.

Clin Breast Cancer. 2019 May 25. pii: S1526-8209(19)30229-0. doi: 10.1016/j.clbc.2019.05.005. [Epub ahead of print]

PMID:
31285177
5.

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel.

Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ.

NPJ Breast Cancer. 2019 Jun 14;5:17. doi: 10.1038/s41523-019-0112-z. eCollection 2019.

6.

Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.

Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J; I-SPY 2 Consortium, Esserman LJ, Hylton NM.

J Magn Reson Imaging. 2019 Apr 26. doi: 10.1002/jmri.26770. [Epub ahead of print]

PMID:
31026118
7.

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.

Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM.

NPJ Breast Cancer. 2019 Apr 16;5:12. doi: 10.1038/s41523-019-0107-9. eCollection 2019.

8.

Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; I-SPY2 Investigators.

NPJ Breast Cancer. 2019 Jan 2;5:2. doi: 10.1038/s41523-018-0096-0. eCollection 2019.

9.

Should we rename low risk cancers?

Esserman LJ, Varma M.

BMJ. 2019 Jan 23;364:k4699. doi: 10.1136/bmj.k4699. No abstract available.

PMID:
30674473
10.

Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.

Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM; ACRIN Trial Team and I-SPY 2 TRIAL Investigators.

J Magn Reson Imaging. 2019 Jun;49(6):1617-1628. doi: 10.1002/jmri.26539. Epub 2018 Oct 22.

PMID:
30350329
11.

Precision risk-based screening might maximize benefit and minimize harm.

Esserman LJ, LaCroix AZ.

Nat Rev Clin Oncol. 2018 Nov;15(11):661-662. doi: 10.1038/s41571-018-0093-0. No abstract available.

PMID:
30218030
12.

Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer.

Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW.

NPJ Breast Cancer. 2018 Sep 5;4:31. doi: 10.1038/s41523-018-0083-5. eCollection 2018.

13.

Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.

Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM; ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators.

Radiology. 2018 Dec;289(3):618-627. doi: 10.1148/radiol.2018180273. Epub 2018 Sep 4.

PMID:
30179110
14.

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; and I-SPY 2 Investigators.

NPJ Breast Cancer. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018. Review. Erratum in: NPJ Breast Cancer. 2019 Jan 2;5:2.

15.

The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia.

Mustoe MM, Lee CM, Melisko ME, Esserman LJ, Rugo HS.

Future Oncol. 2018 Oct;14(24):2461-2469. doi: 10.2217/fon-2018-0178. Epub 2018 Jul 12.

PMID:
30001151
16.

MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.

Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM; ACRIN 6657 Trial Team and I-SPY Investigators Network.

AJR Am J Roentgenol. 2018 Jun;210(6):1376-1385. doi: 10.2214/AJR.17.18323. Epub 2018 Apr 30.

17.

Improved analgesia and reduced post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) pathway for total mastectomy.

Chiu C, Aleshi P, Esserman LJ, Inglis-Arkell C, Yap E, Whitlock EL, Harbell MW.

BMC Anesthesiol. 2018 Apr 16;18(1):41. doi: 10.1186/s12871-018-0505-9.

18.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
19.

Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.

Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM.

Oncotarget. 2017 Dec 20;9(8):7832-7843. doi: 10.18632/oncotarget.23471. eCollection 2018 Jan 30.

20.

Initial Clinical Experience With an Inducible Magnetic Seed System for Preoperative Breast Lesion Localization.

Price ER, Khoury AL, Esserman LJ, Joe BN, Alvarado MD.

AJR Am J Roentgenol. 2018 Apr;210(4):913-917. doi: 10.2214/AJR.17.18345. Epub 2018 Feb 15.

PMID:
29446680
21.

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.

Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ; STO Trialists Group.

J Natl Cancer Inst. 2018 Jul 1;110(7):726-733. doi: 10.1093/jnci/djx270.

22.

The value of embedding: integrated palliative care for patients with metastatic breast cancer.

Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, Belkora J, Esserman LJ, Rugo H.

Breast Cancer Res Treat. 2018 Feb;167(3):703-708. doi: 10.1007/s10549-017-4556-2. Epub 2017 Oct 30.

PMID:
29086230
23.

The WISDOM Study: breaking the deadlock in the breast cancer screening debate.

Esserman LJ; WISDOM Study and Athena Investigators.

NPJ Breast Cancer. 2017 Sep 13;3:34. doi: 10.1038/s41523-017-0035-5. eCollection 2017. Review.

24.

Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.

Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME.

Breast Cancer Res Treat. 2018 Jan;167(1):117-122. doi: 10.1007/s10549-017-4506-z. Epub 2017 Sep 18.

PMID:
28921303
25.

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.

Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L.

Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4.

26.

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS.

Breast Cancer Res Treat. 2017 Nov;166(2):593-601. doi: 10.1007/s10549-017-4428-9. Epub 2017 Aug 4.

27.

Complications After Total Skin-Sparing Mastectomy and Expander-Implant Reconstruction: Effects of Radiation Therapy on the Stages of Reconstruction.

Peled AW, Sears M, Wang F, Foster RD, Alvarado M, Wong J, Ewing CA, Sbitany H, Esserman LJ, Fowble B.

Ann Plast Surg. 2018 Jan;80(1):10-13. doi: 10.1097/SAP.0000000000001186.

PMID:
28671888
28.

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.

Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS.

JAMA Oncol. 2017 Nov 1;3(11):1503-1510. doi: 10.1001/jamaoncol.2017.1261. Erratum in: JAMA Oncol. 2017 Nov 1;3(11):1589.

29.

Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.

Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP.

Breast Cancer Res Treat. 2017 Aug;165(1):161. doi: 10.1007/s10549-017-4350-1. No abstract available.

PMID:
28660429
30.
31.

Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.

Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP.

Breast Cancer Res Treat. 2017 Aug;165(1):151-159. doi: 10.1007/s10549-017-4288-3. Epub 2017 May 13. Erratum in: Breast Cancer Res Treat. 2017 Aug;165(1):161.

PMID:
28503722
32.

Precision surgery and avoiding over-treatment.

Hosseini A, Khoury AL, Esserman LJ.

Eur J Surg Oncol. 2017 May;43(5):938-943. doi: 10.1016/j.ejso.2017.02.003. Epub 2017 Feb 11. Review.

PMID:
28238520
33.

Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.

Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA; Athena Breast Health Network Investigators.

J Natl Cancer Inst. 2017 Jan 27;109(5). doi: 10.1093/jnci/djw290. Print 2017 Jan. Review.

PMID:
28130475
34.

Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.

Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM.

Clin Breast Cancer. 2017 Jun;17(3):e155-e159. doi: 10.1016/j.clbc.2016.12.008. Epub 2016 Dec 29. No abstract available.

PMID:
28110902
35.

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.

Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM; ACRIN 6657 Trial Team and I-SPY Investigators Network.

Tomography. 2016 Dec;2(4):378-387. doi: 10.18383/j.tom.2016.00247.

36.

MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.

Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM; ACRIN Trial team ISPY-1 Investigators.

J Magn Reson Imaging. 2017 Jul;46(1):290-302. doi: 10.1002/jmri.25560. Epub 2016 Dec 16.

37.

Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.

Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS.

JAMA Oncol. 2017 Mar 1;3(3):313-319. doi: 10.1001/jamaoncol.2016.3904.

PMID:
27832260
38.

PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.

Trusheim MR, Shrier AA, Antonijevic Z, Beckman RA, Campbell RK, Chen C, Flaherty KT, Loewy J, Lacombe D, Madhavan S, Selker HP, Esserman LJ.

Clin Pharmacol Ther. 2016 Dec;100(6):713-729. doi: 10.1002/cpt.514. Epub 2016 Oct 19.

39.
40.

The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.

Mukhtar RA, Piper ML, Freise C, Van't Veer LJ, Baehner FL, Esserman LJ.

Am J Transplant. 2017 Jan;17(1):292-295. doi: 10.1111/ajt.14003. Epub 2016 Sep 7.

41.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

42.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.

43.

Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.

Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, Wallstrom G, LaBaer J, Cramer DW, Hollingsworth MA, Anderson KS.

Proteomics Clin Appl. 2016 Jul;10(7):720-31. doi: 10.1002/prca.201500096. Epub 2016 May 17.

44.

Population-based screening for cancer: hope and hype.

Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ.

Nat Rev Clin Oncol. 2016 Sep;13(9):550-65. doi: 10.1038/nrclinonc.2016.50. Epub 2016 Apr 13. Review.

45.

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.

Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM.

PLoS One. 2016 Feb 17;11(2):e0142047. doi: 10.1371/journal.pone.0142047. eCollection 2016.

46.

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN.

Breast Cancer Res Treat. 2016 Feb;155(3):521-30. doi: 10.1007/s10549-016-3701-7. Epub 2016 Feb 13.

PMID:
26875185
47.

Outcomes Following Oncoplastic Reduction Mammoplasty: A Systematic Review.

Piper ML, Esserman LJ, Sbitany H, Peled AW.

Ann Plast Surg. 2016 May;76 Suppl 3:S222-6. doi: 10.1097/SAP.0000000000000720. Review.

PMID:
26808743
48.

Neoadjuvant as Future for Drug Development in Breast Cancer--Response.

DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ; I-SPY2 Investigators.

Clin Cancer Res. 2016 Jan 1;22(1):269. doi: 10.1158/1078-0432.CCR-15-1643. No abstract available.

49.

Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.

Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD; ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators.

Radiology. 2016 Apr;279(1):44-55. doi: 10.1148/radiol.2015150013. Epub 2015 Dec 1.

50.

How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.

Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ.

World J Clin Cases. 2015 Jul 16;3(7):607-13. doi: 10.12998/wjcc.v3.i7.607. Review.

Supplemental Content

Loading ...
Support Center